Sector
PharmaceuticalsOpen
₹242.1Prev. Close
₹242.1Turnover(Lac.)
₹15.32Day's High
₹247.95Day's Low
₹242.152 Week's High
₹32552 Week's Low
₹180Book Value
₹71.65Face Value
₹10Mkt Cap (₹ Cr.)
302.94P/E
20.45EPS
11.84Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 12.3 | 12.3 | 12.3 | 6.15 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 73.33 | 58.93 | 47.57 | 46.06 |
Net Worth | 85.63 | 71.23 | 59.87 | 52.21 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 |
---|---|---|---|
Revenue | 60.75 | 55.84 | 48.76 |
yoy growth (%) | 8.77 | 14.52 | |
Raw materials | -21.87 | -23.65 | -21.06 |
As % of sales | 36.01 | 42.35 | 43.2 |
Employee costs | -3.97 | -4.11 | -3.18 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 |
---|---|---|---|
Profit before tax | 12.74 | 5.99 | 3.26 |
Depreciation | -2.81 | -2.76 | -2.81 |
Tax paid | -3.11 | -1.22 | -1.51 |
Working capital | 14.37 | 10.27 | |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 |
---|---|---|---|
Growth matrix (%) | |||
Revenue growth | 8.77 | 14.52 | |
Op profit growth | 69.47 | 10.59 | |
EBIT growth | 97.21 | 17.67 | |
Net profit growth | 143.67 | 171.62 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,866.1 | 160.85 | 4,47,691.91 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,452.2 | 87.17 | 1,44,798.51 | 430 | 0.55 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,671.8 | 33.98 | 1,34,956.56 | 1,055.94 | 0.78 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,453.25 | 77.72 | 1,16,815.97 | 469 | 0.81 | 2,394 | 201.77 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,110.95 | 25.58 | 1,11,727.19 | 1,700.8 | 0.27 | 4,035.4 | 156.19 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director
FALGUN VALLABHBHAI SAVANI
Executive Director & CEO
JIGNESHBHAI VALLABHBHAI SAVANI
WTD & Executive Director
GHANSHAYAMBHAI BHAGVANBHAI SAVANI
Non Executive Director
Nayna Jignesh Savani
Independent Non Exe. Director
Krishna Mitulbhai Shah
Independent Non Exe. Director
Kajal Chintanbhai Vaghani
Independent Non Exe. Director
Pravin Manjibhai Bhayani
Independent Non Exe. Director
Bintal Bhaveshkumar Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Par Drugs & Chemicals Ltd
Summary
Par Drugs and Chemicals Limited was originally incorporated as a Private Limited Company with the name Par Drugs and Chemicals Private Limited at Bhavnagar, Gujarat. On 26 February 1999. Subsequently, the Company was converted into a Public Limited Company and the name was changed to Par Drugs and Chemicals Limited on 5 November 2018.The Company is primarily engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets. APIs, also known as bulk drugs or bulk actives are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.The Company currently own and operate two manufacturing facilities at Bhavnagar and Ankleshwar in the Gujarat. It currently have three manufacturing blocks at Bhavnagar facility for different products. The Bhavnagar facility certified by food & drugs control administration. During the year 2011, the company has added two manufacturing block out of three at Chitra, Bhavnagar facility. One is dedicated facility for its main API and another one is for Fine Chemicals.The Product portfolio presently comprises 12 APIs and 6 Fine Chemicals which are marketed domestically and exported. The Company supplies its products to approximately 16 countries, including both direct and indirect exports. The Key customers include Essential Drugs Company Limited, Tauru
Read More
The Par Drugs & Chemicals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹246.2 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Par Drugs & Chemicals Ltd is ₹302.94 Cr. as of 18 Sep ‘24
The PE and PB ratios of Par Drugs & Chemicals Ltd is 20.45 and 3.48 as of 18 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Par Drugs & Chemicals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Par Drugs & Chemicals Ltd is ₹180 and ₹325 as of 18 Sep ‘24
Par Drugs & Chemicals Ltd's CAGR for 5 Years at 60.40%, 3 Years at 17.30%, 1 Year at 32.26%, 6 Month at 16.12%, 3 Month at 7.01% and 1 Month at 1.69%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice